EICHOR
● Active Not Recruiting
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
Condition: Exocrine Pancreas Carcinoma · Malignant Solid Neoplasm · Ovarian Low Grade Serous Adenocarcinoma · Sponsor: National Cancer Institute (NCI)
About this study
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (266)
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | — |
| University of South Alabama Mitchell Cancer Institute | Mobile, Alabama, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| UC San Diego Health System - Encinitas | Encinitas, California, United States | — |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | — |
| VA Palo Alto Health Care System | Palo Alto, California, United States | — |
| UC San Diego Medical Center - Hillcrest | San Diego, California, United States | — |
| UCHealth University of Colorado Hospital | Aurora, Colorado, United States | — |
| Poudre Valley Hospital | Fort Collins, Colorado, United States | — |
| Cancer Care and Hematology-Fort Collins | Fort Collins, Colorado, United States | — |
| UCHealth Greeley Hospital | Greeley, Colorado, United States | — |
| Medical Center of the Rockies | Loveland, Colorado, United States | — |
+ 254 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05554367